Correction: Toripalimab or placebo with chemotherapy as initial therapy for advanced nasopharyngeal carcinoma in a multicenter, randomized phase 3 trial

Correct errors and clarify data labels and censoring information in the published article and its supplementary materials.

Numerical and labeling corrections: The correction updates maintenance-treatment counts, the Fig. 2 data cutoff date, selected Table 3 and Supplementary Table S13 values, the Supplementary Table S10 footnote, and the Fig. 2 Source Data column label.
Clarifications: For specified survival-analysis Source Data, 0 denotes an event and 1 denotes censoring. Supplementary Table S15 explains why three patients who later died were censored in PFS and duration-of-response analyses.

The correct number continuing maintenance treatment is 233 (80.6%), not 231 (79.9%); the Extended Data Fig. 1 legend total is also corrected to 233.
The Fig. 2 data cutoff date is 18 February 2021, not 18 February 2020.
In the Toripalimab + GP group, any-grade thrombocytopenia is 92 (63.0), and grade ≥3 hypochloremia is 2 (1.4).
The Supplementary Table S10 footnote now says “determined by BIRC”; Supplementary Table S13 reports “Alive” as 219 (75.8); and the Fig. 2 Source Data column is labeled “OS,” not “PFS.”
Three patients who later died were censored for PFS and duration-of-response analyses after missing at least two consecutive scheduled tumor assessments or starting new anticancer therapy before progression or death was documented.

The correction states that the study’s results and conclusions are unaffected.

Amendments were incorporated into the article’s HTML and PDF versions, including its text, table, figures, and Source Data.